[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 67,179,776
  • Shares Outstanding, K 105,720
  • Annual Sales, $ 14,343 M
  • Annual Income, $ 4,505 M
  • EBIT $ 3,629 M
  • EBITDA $ 4,173 M
  • 60-Month Beta 0.25
  • Price/Sales 4.63
  • Price/Cash Flow 14.98
  • Price/Book 2.12

Options Overview Details

View History
  • Implied Volatility 32.49% (+0.79%)
  • Historical Volatility 41.34%
  • IV Percentile 18%
  • IV Rank 27.53%
  • IV High 49.01% on 10/10/25
  • IV Low 26.22% on 11/26/25
  • Expected Move (DTE 5) 11.18 (1.76%)
  • Put/Call Vol Ratio 0.96
  • Today's Volume 1,181
  • Volume Avg (30-Day) 1,866
  • Put/Call OI Ratio 0.93
  • Today's Open Interest 43,019
  • Open Int (30-Day) 42,913
  • Expected Range 624.27 to 646.63

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 29 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $8.47
  • Number of Estimates 6
  • High Estimate $11.13
  • Low Estimate $6.29
  • Prior Year $10.72
  • Growth Rate Est. (year over year) -20.99%

Price Performance

See More
Period Period Low Period High Performance
1-Month
591.52 +7.43%
on 06/02/26
730.59 -13.02%
on 05/13/26
-66.82 (-9.51%)
since 05/05/26
3-Month
591.52 +7.43%
on 06/02/26
788.69 -19.43%
on 03/10/26
-129.48 (-16.93%)
since 03/05/26
52-Week
485.00 +31.02%
on 06/06/25
821.11 -22.61%
on 01/09/26
+152.38 (+31.54%)
since 06/05/25

Most Recent Stories

More News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN

NEW YORK , June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN). Such investors...

REGN : 635.45 (+1.07%)
Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO

TARRYTOWN, N.Y., June 04, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new clinical data and research from its metabolic disease, ophthalmology and rare...

REGN : 635.45 (+1.07%)
Why Regeneron (REGN) Stock Is Trading Up Today

Why Regeneron (REGN) Stock Is Trading Up Today

REGN : 635.45 (+1.07%)
2 S&P 500 Stocks with Solid Fundamentals and 1 We Find Risky

2 S&P 500 Stocks with Solid Fundamentals and 1 We Find Risky

MA : 491.08 (+1.93%)
SYK : 305.66 (+1.48%)
REGN : 635.45 (+1.07%)
Vertex Pharmaceuticals Stock: Is VRTX Underperforming the Healthcare Sector?

Despite Vertex Pharmaceuticals' underperformance relative to the healthcare sector over the past year, Wall Street analysts remain strongly optimistic about the stock’s prospects.

XLV : 153.01 (+0.61%)
VRTX : 446.83 (+1.15%)
REGN : 635.45 (+1.07%)
AMGN : 349.58 (+1.15%)
Is Regeneron Pharmaceuticals Stock Underperforming the Dow?

Regeneron Pharmaceuticals has underperformed the Dow Jones over the past year, and analysts remain moderately optimistic about the stock’s outlook.

VRTX : 446.83 (+1.15%)
$DOWI : 50,866.78 (-1.35%)
REGN : 635.45 (+1.07%)
3 Nasdaq 100 Stocks We Find Risky

3 Nasdaq 100 Stocks We Find Risky

INTC : 99.17 (-11.28%)
KHC : 22.58 (+0.49%)
REGN : 635.45 (+1.07%)
Regeneron’s Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak

Inmazeb ® (a three-antibody cocktail consisting of maftivimab, atoltivimab and odesivimab-ebgn) was the first Ebola treatment approved by the U.S. Food and Drug Administration, indicated specifically...

REGN : 635.45 (+1.07%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN

NEW YORK , May 28, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN).  Such investors...

REGN : 635.45 (+1.07%)
Are Wall Street Analysts Predicting Regeneron Pharmaceuticals Stock Will Climb or Sink?

Regeneron Pharmaceuticals has underperformed the broader market over the past year, and analysts remain reasonably bullish about the stock’s long term prospects.

XLV : 153.01 (+0.61%)
$SPX : 7,383.74 (-2.64%)
REGN : 635.45 (+1.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting serious medical conditions. The company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. The company also...

See More

Key Turning Points

3rd Resistance Point 648.88
2nd Resistance Point 644.85
1st Resistance Point 640.15
Last Price 635.45
1st Support Level 631.42
2nd Support Level 627.39
3rd Support Level 622.69

See More

52-Week High 821.11
Fibonacci 61.8% 692.72
Fibonacci 50% 653.06
Last Price 635.45
Fibonacci 38.2% 613.39
52-Week Low 485.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.